{ "instance": { "d888266d10q.htm": { "axisCustom": 1, "axisStandard": 19, "contextCount": 94, "dts": { "calculationLink": { "local": [ "md-20200331_cal.xml" ] }, "definitionLink": { "local": [ "md-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d888266d10q.htm" ] }, "labelLink": { "local": [ "md-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "md-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "md-20200331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 378, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 4, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 9 }, "keyCustom": 28, "keyStandard": 265, "memberCustom": 21, "memberStandard": 24, "nsprefix": "md", "nsuri": "http://www.mednax.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.mednax.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Fair Value Measurements", "role": "http://www.mednax.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Accounts Receivable and Net Revenue", "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenue", "shortName": "Accounts Receivable and Net Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Discontinued Operations", "role": "http://www.mednax.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Accounts Payable and Accrued Expenses", "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Common and Common Equivalent Shares", "role": "http://www.mednax.com/role/CommonAndCommonEquivalentShares", "shortName": "Common and Common Equivalent Shares", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans", "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans", "shortName": "Stock Incentive Plans and Stock Purchase Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:CommonStockRepurchasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Common Stock Repurchase Programs", "role": "http://www.mednax.com/role/CommonStockRepurchasePrograms", "shortName": "Common Stock Repurchase Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:CommonStockRepurchasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Commitments and Contingencies", "role": "http://www.mednax.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Subsequent Event", "role": "http://www.mednax.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)", "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies", "shortName": "Basis of Presentation and New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Consolidated Balance Sheets (Unaudited)", "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Cash Equivalents and Investments (Tables)", "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables", "shortName": "Cash Equivalents and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.mednax.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Accounts Receivable and Net Revenue (Tables)", "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables", "shortName": "Accounts Receivable and Net Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Common and Common Equivalent Shares (Tables)", "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables", "shortName": "Common and Common Equivalent Shares (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Subsequent Event (Table)", "role": "http://www.mednax.com/role/SubsequentEventTable", "shortName": "Subsequent Event (Table)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)", "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail", "shortName": "Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)", "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "shortName": "Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)", "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail", "shortName": "Cash Equivalents and Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)", "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail", "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "md:MoneyMarketFundsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)", "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "md:MoneyMarketFundsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)", "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails", "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)", "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail", "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)", "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail", "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "2", "first": true, "lang": null, "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)", "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail", "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "md:AccountsReceivableAndNetRevenueDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "2", "first": true, "lang": null, "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Discontinued Operations - Additional Information (Detail)", "role": "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail", "shortName": "Discontinued Operations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)", "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail", "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2019To03_31_2019", "decimals": "-5", "first": true, "lang": null, "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)", "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail", "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2019To03_31_2019", "decimals": "-5", "first": true, "lang": null, "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)", "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail", "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2019To03_31_2019", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)", "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail", "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-5", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Consolidated Statements of Income", "role": "http://www.mednax.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "lang": null, "name": "md:PracticeSalariesAndBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn08_31_2018", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)", "role": "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn08_31_2018", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Subsequent Event - Additional information (Detail)", "role": "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail", "shortName": "Subsequent Event - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)", "role": "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "shortName": "Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Consolidated Statements of Equity", "role": "http://www.mednax.com/role/ConsolidatedStatementsOfEquity", "shortName": "Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements", "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements", "shortName": "Basis of Presentation and New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Coronavirus Pandemic (\"COVID-19\")", "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19", "shortName": "Coronavirus Pandemic (\"COVID-19\")", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Cash Equivalents and Investments", "role": "http://www.mednax.com/role/CashEquivalentsAndInvestments", "shortName": "Cash Equivalents and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d888266d10q.htm", "contextRef": "P01_01_2020To03_31_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.", "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts receivable and net revenue disclosure.", "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]", "terseLabel": "Accounts Receivable and Net Revenue" } } }, "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenue" ], "xbrltype": "textBlockItemType" }, "md_AccountsReceivableRetained": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accounts receivable retained.", "label": "Accounts Receivable Retained", "terseLabel": "Accounts receivable retained" } } }, "localname": "AccountsReceivableRetained", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_AccruedContingentConsiderationLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued contingent consideration liability current.", "label": "Accrued Contingent Consideration Liability Current", "terseLabel": "Accrued contingent consideration" } } }, "localname": "AccruedContingentConsiderationLiabilityCurrent", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "md_AccruedPayrollTaxesAndBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued payroll taxes and benefits current.", "label": "Accrued Payroll Taxes And Benefits Current", "terseLabel": "Accrued payroll taxes and benefits" } } }, "localname": "AccruedPayrollTaxesAndBenefitsCurrent", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "md_AmendedAndRestatedTwoThousandEightPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended and restated two thousand eight plan.", "label": "Amended and Restated Two Thousand Eight Plan [Member]", "terseLabel": "Amended and Restated 2008 Plan [Member]" } } }, "localname": "AmendedAndRestatedTwoThousandEightPlanMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_BasisOfPresentationAndNewAccountingPronouncementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Basis of Presentation and New Accounting Pronouncements [Table]" } } }, "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_BasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Basis Of Presentation [Line Items]" } } }, "localname": "BasisOfPresentationLineItems", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value Of contingent consideration liability.", "label": "Business Combination Contingent Consideration Liability Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "md_CashEquivalentsAndInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Equivalents And Investments [Line Items]" } } }, "localname": "CashEquivalentsAndInvestmentsLineItems", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_CashEquivalentsAndInvestmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Equivalents and Investments [Table]" } } }, "localname": "CashEquivalentsAndInvestmentsTable", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_CommonStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock [Line Items]", "label": "Common Stock [Line Items]", "terseLabel": "Common Stock [Line Items]" } } }, "localname": "CommonStockLineItems", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_CommonStockRepurchasesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Entire disclosure of common stock repurchases.", "label": "Common Stock Repurchases [Text Block]", "terseLabel": "Common Stock Repurchase Programs" } } }, "localname": "CommonStockRepurchasesTextBlock", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchasePrograms" ], "xbrltype": "textBlockItemType" }, "md_CommonStockTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock [Table]", "label": "Common Stock [Table]", "terseLabel": "Common Stock [Table]" } } }, "localname": "CommonStockTable", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_ContractedManagedCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracted Managed Care [Member]", "label": "Contracted Managed Care [Member]", "terseLabel": "Contracted Managed Care [Member]" } } }, "localname": "ContractedManagedCareMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "domainItemType" }, "md_ContributionsInAidOfReimbursementOfLostRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.", "label": "Contributions In Aid Of Reimbursement of Lost Revenue", "terseLabel": "Reimbursement of Lost Revenue" } } }, "localname": "ContributionsInAidOfReimbursementOfLostRevenue", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]", "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]", "terseLabel": "Coronavirus Pandemic (\"COVID-19\")" } } }, "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19" ], "xbrltype": "textBlockItemType" }, "md_CovidNinenteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covid Ninenteen [Member]", "label": "Covid Ninenteen [Member]", "terseLabel": "COVID-19 [Member]" } } }, "localname": "CovidNinenteenMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_DeferredTaxAssetsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets [Axis]" } } }, "localname": "DeferredTaxAssetsAxis", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_DeferredTaxAssetsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets [Domain]" } } }, "localname": "DeferredTaxAssetsDomain", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group including discontinued operation accrued professional liabilities.", "label": "Disposal Group Including Discontinued Operation Accrued Professional Liabilities", "terseLabel": "Accrued professional liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated Earnings Before Interest Taxes Depreciation And Amortization", "label": "Estimated Earnings Before Interest Taxes Depreciation And Amortization", "terseLabel": "Estimated EBITDA" } } }, "localname": "EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_ExtraordinaryItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extraordinary Items [Abstract]", "label": "Extraordinary Items [Abstract]" } } }, "localname": "ExtraordinaryItemsAbstract", "nsuri": "http://www.mednax.com/20200331", "xbrltype": "stringItemType" }, "md_ExtraordinaryItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extraordinary Items [Axis]", "label": "Extraordinary Items [Axis]" } } }, "localname": "ExtraordinaryItemsAxis", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_ExtraordinaryItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extraordinary Items [Axis]", "label": "Extraordinary Items [Domain]" } } }, "localname": "ExtraordinaryItemsDomain", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of financial instruments measured at carrying amount.", "label": "Financial Instruments Measured At Carrying Amount Table Text Block", "verboseLabel": "Financial Instruments Measured At Carrying Amount" } } }, "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "md_ForecastForFirstQuarterOf2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forecast For First Quarter Of 2021 [Member]", "label": "Forecast For First Quarter Of 2021 [Member]", "terseLabel": "Forecast For First Quarter Of 2021 [Member]" } } }, "localname": "ForecastForFirstQuarterOf2021Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_ForecastForFourthQuarterOf2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forecast For Fourth Quarter Of 2020 [Member]", "label": "Forecast For Fourth Quarter Of 2020 [Member]", "terseLabel": "Forecast For Fourth Quarter Of 2020 [Member]" } } }, "localname": "ForecastForFourthQuarterOf2020Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_ForecastForSecondAndThirdQuartersOf2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forecast For Second And Third Quarters Of 2020 [Member]", "label": "Forecast For Second And Third Quarters Of 2020 [Member]", "terseLabel": "Forecast For Second And Third Quarters Of 2020 [Member]" } } }, "localname": "ForecastForSecondAndThirdQuartersOf2020Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_ForecastForSecondQuarterOf2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forecast For Second Quarter Of 2021 [Member]", "label": "Forecast For Second Quarter Of 2021 [Member]", "terseLabel": "Forecast For Second Quarter Of 2021 [Member]" } } }, "localname": "ForecastForSecondQuarterOf2021Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_HospitalsContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hospitals Contracts [Member]", "label": "Hospitals Contracts [Member]", "terseLabel": "Hospital contract administrative fees [Member]" } } }, "localname": "HospitalsContractsMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "domainItemType" }, "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share", "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]", "terseLabel": "Loss (income) from continuing operations:" } } }, "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "md_IncreaseDecreaseInAccruedSalariesAndBonuses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in accrued salaries and bonuses.", "label": "Increase Decrease In Accrued Salaries And Bonuses", "verboseLabel": "Net decrease in accrued salaries and bonuses" } } }, "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long term debt and capital lease obligations excluding long term line of credit.", "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit", "verboseLabel": "Long-term debt and finance lease liabilities, net" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "md_MaximumConsiderationReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum consideration receivable.", "label": "Maximum Consideration Receivable", "terseLabel": "Maximum consideration receivable" } } }, "localname": "MaximumConsiderationReceivable", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_MoneyMarketFundsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of money market funds.", "label": "Money Market Funds Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsFairValueDisclosure", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "md_MutualFundsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Mutual funds fair value disclosure.", "label": "Mutual Funds Fair Value Disclosure", "terseLabel": "Mutual Funds" } } }, "localname": "MutualFundsFairValueDisclosure", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]", "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]", "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]" } } }, "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1996 non-qualified employee stock purchase plan.", "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]", "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]" } } }, "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_NorthAmericanPartnersInAnesthesiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "North American Partners In Anesthesia [member].", "label": "North American Partners In Anesthesia [Member]", "terseLabel": "North American Partners In Anesthesia [Member]" } } }, "localname": "NorthAmericanPartnersInAnesthesiaMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "domainItemType" }, "md_PercentageIncreaseDecreaseInSalaryAndWage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage Increase Decrease In Salary And Wage.", "label": "Percentage Increase Decrease In Salary And Wage", "terseLabel": "Decrease In Salary | %" } } }, "localname": "PercentageIncreaseDecreaseInSalaryAndWage", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "md_PercentageOfDeferredPaymentOfSocialSecurityTaxes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage Of Deferred Payment Of Social Security Taxes.", "label": "Percentage Of Deferred Payment Of Social Security Taxes", "terseLabel": "Deferred Payment Of Social Security Taxes | %" } } }, "localname": "PercentageOfDeferredPaymentOfSocialSecurityTaxes", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of net patient service revenue by type payor.", "label": "Percentage Of Net Patient Service Revenue By Type Of Payor", "terseLabel": "Percentage of net patient service revenue" } } }, "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "percentItemType" }, "md_PracticeSalariesAndBenefits": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Practice salaries and benefits.", "label": "Practice Salaries and Benefits", "terseLabel": "Practice salaries and benefits" } } }, "localname": "PracticeSalariesAndBenefits", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "md_PracticeSuppliesAndOtherOperatingExpenses": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.", "label": "Practice Supplies And Other Operating Expenses", "terseLabel": "Practice supplies and other operating expenses" } } }, "localname": "PracticeSuppliesAndOtherOperatingExpenses", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.", "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue", "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue" } } }, "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_RuralAreaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rural Area [Member]", "label": "Rural Area [Member]", "terseLabel": "Rural Area [Member]" } } }, "localname": "RuralAreaMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_ScheduleOfFinancingReceivablesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of financing receivables.", "label": "Schedule Of Financing Receivables [Line Items]", "terseLabel": "Schedule Of Financing Receivables [Line Items]" } } }, "localname": "ScheduleOfFinancingReceivablesLineItems", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "stringItemType" }, "md_Seniorunsecurdnotes2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SeniorUnsecurdNotes2023 [Member]", "terseLabel": "Senior Unsecurd Notes 2023 [Member]" } } }, "localname": "Seniorunsecurdnotes2023Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_Seniorunsecurdnotes2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SeniorUnsecurdNotes2027 [Member]", "terseLabel": "Senior Unsecurd Notes 2027 [Member]" } } }, "localname": "Seniorunsecurdnotes2027Member", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_StockIssuedDuringPeriodSharesStockSwaps": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period shares stock swaps.", "label": "Stock Issued During Period, Shares, Stock Swaps", "terseLabel": "Stock swaps, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockSwaps", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "md_StockIssuedDuringPeriodValueStockSwaps": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value stock swaps.", "label": "Stock Issued During Period Value Stock Swaps", "terseLabel": "Stock swaps" } } }, "localname": "StockIssuedDuringPeriodValueStockSwaps", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "md_SupplementaryLeverageRatioRequired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplementary Leverage Ratio Required.", "label": "Supplementary Leverage Ratio Required", "terseLabel": "Leverage ratio" } } }, "localname": "SupplementaryLeverageRatioRequired", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "md_TransactionRelatedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transaction related expenses.", "label": "Transaction Related Expenses", "verboseLabel": "Transaction related expenses" } } }, "localname": "TransactionRelatedExpenses", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]", "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]", "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_TwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Thousand Twenty Seven [Member]", "terseLabel": "2027 Notes [Member]" } } }, "localname": "TwoThousandTwentySevenMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "md_TwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Thousand Twenty Three [Member]", "terseLabel": "2023 Notes [Member]" } } }, "localname": "TwoThousandTwentyThreeMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "md_UnnamedCorporateJointVentureOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unnamed Corporate Joint Venture [Member]", "label": "Unnamed Corporate Joint Venture One [Member]" } } }, "localname": "UnnamedCorporateJointVentureOneMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_UnnamedCorporateJointVentureTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Unnamed Corporate Joint Venture Two [Member]" } } }, "localname": "UnnamedCorporateJointVentureTwoMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_UrbanAreaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Urban Area [Member]", "label": "Urban Area [Member]", "terseLabel": "Urban Area [Member]" } } }, "localname": "UrbanAreaMember", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "md_WorkingCapitalTrueUp": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Working capital true up.", "label": "Working Capital True Up", "terseLabel": "Working capital true up" } } }, "localname": "WorkingCapitalTrueUp", "nsuri": "http://www.mednax.com/20200331", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r132", "r168", "r170", "r265", "r266" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r161", "r225" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r133", "r223" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Accounts payable and accrued expenses, total" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r134", "r135" ], "calculation": { "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Gross, Current", "terseLabel": "Gross accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r25", "r42", "r134", "r135", "r169" ], "calculation": { "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 26.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail", "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r37", "r235", "r252" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r30", "r31", "r57" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued salaries and bonuses" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r43" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r174", "r176", "r188", "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherCorporateBondsMember": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Investments in corporate fixed maturity debt securities classified as other.", "label": "Other Corporate Bonds [Member]", "verboseLabel": "Corporate Securities [Member]" } } }, "localname": "AllOtherCorporateBondsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r176", "r185", "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r48", "r136", "r143" ], "calculation": { "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "negatedLabel": "Allowance for contractual adjustments and uncollectibles" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r101", "r220" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of premiums, discounts and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r130", "r233", "r251" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r27", "r29", "r68" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 23.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r16", "r18", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r178", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r24", "r49", "r103" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 24.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents of continuing operations at end of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.", "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r98", "r217" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash used in financing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r15", "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash used in investing activities - discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r15", "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Net cash provided by operating activities - discontinued operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "verboseLabel": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r62", "r160", "r240", "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r159", "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r63" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, aggregate shares authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r41", "r165" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r41" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,150 and 84,248 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r36", "r37", "r38", "r234", "r236", "r250" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r59", "r219" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt Instrument Interest Rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "verboseLabel": "Schedule of Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r104", "r195", "r196" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r191", "r192", "r194" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 22.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred income tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r191", "r192", "r193" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r101", "r127" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 11.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Net Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock Incentive Plans and Stock Purchase Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r2", "r3", "r18" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]", "terseLabel": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]", "verboseLabel": "Subsequent Event [Line Items]" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "negatedPeriodEndLabel": "Less cash and cash equivalents of discontinued operations at end of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows", "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r16", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r101", "r149", "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "terseLabel": "Preliminary and incremental gain loss on sale" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r23", "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Net loss:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r107", "r111", "r114", "r115", "r116", "r119", "r246", "r263" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]", "terseLabel": "Weighted average common shares:" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r107", "r111", "r114", "r115", "r116", "r119", "r246", "r263" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Common and Common Equivalent Shares" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentShares" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method ownership percentage in joint venture" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r171", "r172", "r173", "r210", "r227" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r209", "r210", "r211", "r212", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r171", "r172", "r173", "r210", "r228" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r171", "r172", "r173", "r210", "r229" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r171", "r172", "r173", "r210", "r230" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r222" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r148" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 19.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r101", "r203" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Gain loss on sale of business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r146", "r147" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 18.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GovernmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization that is the governing authority of a community.", "label": "Government [Member]", "terseLabel": "Government [Member]" } } }, "localname": "GovernmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]", "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]" } } }, "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "stringItemType" }, "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Health Care Organization Revenue and Expense [Abstract]" } } }, "localname": "HealthCareOrganizationRevenueAndExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_HealthCareOrganizationRevenueSourcesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by major payor source of revenue for health care organizations.", "label": "Health Care Organization, Revenue Sources [Axis]", "terseLabel": "Health Care Organization, Revenue Sources [Axis]" } } }, "localname": "HealthCareOrganizationRevenueSourcesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "stringItemType" }, "us-gaap_HealthCareOrganizationRevenueSourcesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Major payor source of revenue for health care organizations.", "label": "Health Care Organization, Revenue Sources [Domain]", "terseLabel": "Health Care Organization, Revenue Sources [Domain]" } } }, "localname": "HealthCareOrganizationRevenueSourcesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCarePatientServiceMember": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.", "label": "Health Care, Patient Service [Member]", "terseLabel": "Net patient service revenue [Member]" } } }, "localname": "HealthCarePatientServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r138" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 25.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Debt Securities, Held-to-maturity, Current", "verboseLabel": "Short-term investments" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r75", "r107", "r231", "r243", "r264" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r200" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "(Loss) income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r73", "r79", "r111", "r114", "r115", "r241", "r244", "r246", "r260" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "verboseLabel": "Basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r73", "r79", "r111", "r114", "r115", "r116", "r246", "r260", "r263" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "verboseLabel": "Diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]", "terseLabel": "Loss from discontinued operations:" } } }, "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r19", "r79", "r261" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 14.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Loss from discontinued operations", "terseLabel": "Loss on classification as held for sale", "verboseLabel": "Loss from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome", "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r77", "r79", "r113", "r114", "r115", "r246", "r261", "r263" ], "lang": { "en-US": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "verboseLabel": "Basic" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r113", "r114", "r115", "r207" ], "lang": { "en-US": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "verboseLabel": "Diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r76", "r101", "r128", "r141", "r242", "r259" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "verboseLabel": "Equity in earnings of unconsolidated affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r9", "r10", "r11", "r12", "r13", "r14", "r17", "r20", "r21", "r22", "r153", "r154" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail", "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r129", "r197" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r65", "r239", "r258" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 29.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "verboseLabel": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve", "terseLabel": "Long-term professional liabilities" } } }, "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r112", "r118" ], "calculation": { "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted average number of dilutive common share equivalents" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r74", "r126", "r218", "r220", "r247" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r31", "r32", "r57" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r81", "r83", "r84" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "verboseLabel": "Investment and other (expense) income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r268", "r269", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r268", "r269", "r270", "r271" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Short-term investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r140", "r232", "r248", "r272" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Cash Equivalents and Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r56" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r47", "r237", "r255" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r16", "r18", "r152" ], "calculation": { "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Credit Facility Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r60", "r163", "r164" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": { "auth_ref": [ "r160" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).", "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current", "terseLabel": "Accrued professional liabilities" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": { "auth_ref": [ "r160" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).", "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent", "terseLabel": "Long-term professional liabilities" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "verboseLabel": "Cash equivalents" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash (used in) provided by financing activities\u2014continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r98" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r98", "r99", "r102" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r98", "r99", "r102" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r71", "r72", "r78", "r102", "r118", "r245", "r262" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "definitionGuidance": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r38", "r236", "r253" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "verboseLabel": "Notes Payable Fair Value Disclosure" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r222" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r222" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r221" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 21.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use\u00a0assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r106", "r108", "r125", "r208" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and New Accounting Pronouncements" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r30", "r31", "r32", "r57" ], "calculation": { "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 28.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 20.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r69", "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized holding loss on investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 31.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payments of contingent consideration liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedLabel": "Payments of contingent consideration liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r92" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 34.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r95" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 36.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payments for credit facility amendment and financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r87" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition payments, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r89" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r178", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r26", "r28", "r145" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 27.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r90" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 33.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 35.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from issuance of senior notes" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r91", "r105" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Borrowings on credit agreement" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r86" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "verboseLabel": "Proceeds from maturities or sales of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "verboseLabel": "Proceeds from sales of businesses" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "verboseLabel": "Other revenue [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r71", "r72", "r97", "r130", "r131", "r200", "r201", "r202", "r205", "r206" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "definitionGuidance": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r34", "r35", "r150", "r256" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 17.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r93", "r105" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 30.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Payments on credit agreement" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": { "auth_ref": [ "r93" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 32.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).", "label": "Repayments of Long-term Capital Lease Obligations", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "RepaymentsOfLongTermCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r101", "r156", "r157", "r158" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 12.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "verboseLabel": "Transformational and restructuring related expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r44", "r166", "r254" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r167", "r168" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts Receivable, Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "verboseLabel": "Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r9", "r10", "r11", "r12", "r13", "r14", "r17", "r20", "r21", "r22", "r153", "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Summary Of Major Classes of Assets And Liabilities" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventTable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of the major payor source of revenue for health care organizations.", "label": "Schedule of Revenue Sources, Health Care Organization [Table]", "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]" } } }, "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r178", "r186" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r121", "r122", "r123", "r124", "r215", "r216" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Percentage of Net Revenue" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfPayMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.", "label": "Self-Pay [Member]", "terseLabel": "Private-Pay Patients [Member]" } } }, "localname": "SelfPayMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r175", "r181" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Vesting period of options, maximum years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares Paid for Tax Withholding for Share Based Compensation", "terseLabel": "Number of shares withheld to satisfy minimum statutory tax withholding obligations" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r39", "r40", "r41", "r165" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r64", "r165" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfEquity", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfEquity", "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail", "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails", "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r40", "r41", "r165", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r40", "r41", "r165", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Forfeitures of restricted stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r40", "r41", "r165", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross", "terseLabel": "Issuance of restricted stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r40", "r41", "r166", "r177", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Gross", "terseLabel": "Issuance of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Common stock authorized for repurchase" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Company's Common stock repurchased" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r40", "r41", "r165", "r166" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchased common stock, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r40", "r41", "r165", "r166" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchased common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r41", "r45", "r46", "r137" ], "calculation": { "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r198", "r199", "r204" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/ConsolidatedStatementsOfEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail", "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ThirdPartyPayorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.", "label": "Third-Party Payor [Member]", "terseLabel": "Other Third-Parties [Member]" } } }, "localname": "ThirdPartyPayorMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r171", "r238" ], "lang": { "en-US": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "verboseLabel": "Federal Home Loan Securities [Member]" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r171", "r267" ], "lang": { "en-US": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "verboseLabel": "Municipal Debt Securities [Member]" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r110", "r116" ], "calculation": { "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted average number of common and common equivalent shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r116" ], "calculation": { "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail", "http://www.mednax.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r23": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r273": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r274": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r275": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r276": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r277": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r278": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" } }, "version": "2.1" }